Recombinant Human KIF3A Protein, N-His from ProteoGenix; catalogue ARO-P12368; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Title: Introduction to Recombinant Human KIF3A Protein
Recombinant human KIF3A protein, also known as kinesin family member 3A, is a motor protein that plays a crucial role in intracellular transport and cell division. This protein is highly conserved among different species and is essential for the proper functioning of various cellular processes. In this article, we will explore the structure, activity, and applications of recombinant human KIF3A protein.
Title: Structure of Recombinant Human KIF3A Protein
Recombinant human KIF3A protein is composed of 747 amino acids and has a molecular weight of approximately 85 kDa. It belongs to the kinesin superfamily of proteins and contains a conserved motor domain at the N-terminus, a coiled-coil region, and a C-terminal tail. The motor domain is responsible for ATP hydrolysis and microtubule binding, while the coiled-coil region allows for dimerization with other kinesin proteins. The C-terminal tail is involved in cargo binding and regulating the activity of the motor domain.
Title: Activity of Recombinant Human KIF3A Protein
Recombinant human KIF3A protein is a microtubule-based motor protein that moves along microtubules in a process called processive movement. It uses the energy from ATP hydrolysis to move towards the plus end of the microtubule. This movement is essential for various intracellular transport processes, such as the transport of organelles, vesicles, and protein complexes. KIF3A is also involved in the formation and maintenance of cilia, which are hair-like structures on the cell surface that play a crucial role in cell signaling and sensory functions.
Title: Applications of Recombinant Human KIF3A Protein
Recombinant human KIF3A protein has various applications in both research and medicine. One of the key applications is in studying the mechanism of intracellular transport and its role in various cellular processes. Researchers can use recombinant KIF3A protein to study its interaction with other proteins, microtubules, and cargo molecules. This can provide insights into the regulation of intracellular transport and its role in diseases such as neurodegeneration and cancer.
In addition, recombinant human KIF3A protein has potential therapeutic applications. Mutations in the KIF3A gene have been linked to various diseases, including Bardet-Biedl syndrome, a rare genetic disorder that affects multiple organ systems. Recombinant KIF3A protein can be used to study the effects of these mutations and potentially develop treatments for these diseases. Furthermore, KIF3A has been identified as a potential target for drug development in cancer therapy. Inhibition of KIF3A activity has been shown to reduce tumor growth and metastasis in preclinical studies.
Title: Production of Recombinant Human KIF3A Protein
Recombinant human KIF3A protein is produced using recombinant DNA technology. The gene encoding KIF3A is cloned into a suitable expression vector and introduced into host cells, such as bacteria or mammalian cells. The cells are then grown in culture, and the recombinant protein is purified using various chromatography techniques. The purified protein can be used for in vitro studies or as an antigen for antibody production.
Conclusion:
Recombinant human KIF3A protein is a crucial motor protein involved in intracellular transport and cell division. Its structure, activity, and applications make it a valuable tool for studying cellular processes and potential therapeutic target for various diseases. With ongoing research, the potential of recombinant KIF3A protein in advancing our understanding of cellular biology and developing treatments for diseases is vast.
ProteoGenix catalogue number ARO-P12368. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 38.95 kDa; Fragment: Lys16-Ile345; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
